Rare uterine cancer

Rare uterine cancer (Orphanet code 213564) is a grouping term that encompasses uncommon malignant neoplasms arising from the uterus that do not fall into the more frequently diagnosed categories of endometrial endometrioid carcinoma or typical uterine leiomyosarcoma. This category includes a heterogeneous collection of rare histological subtypes such as uterine carcinosarcoma (malignant mixed Müllerian tumor), uterine clear cell carcinoma, uterine serous carcinoma, undifferentiated uterine sarcoma, endometrial stromal sarcoma, and other exceptionally rare uterine malignancies. These cancers primarily affect the female reproductive system, specifically the uterine corpus, but may spread to the pelvic organs, peritoneum, lymph nodes, lungs, and other distant sites. Key symptoms commonly include abnormal uterine bleeding (particularly postmenopausal bleeding), pelvic pain or pressure, an enlarging pelvic mass, and unexplained weight loss. Some patients may present with vaginal discharge or symptoms related to metastatic disease. Diagnosis typically involves endometrial biopsy or curettage, imaging studies (ultrasound, CT, or MRI), and histopathological examination. Due to the rarity and aggressive nature of many of these subtypes, they are often diagnosed at more advanced stages compared to common endometrial cancers. Treatment generally involves surgical management, including hysterectomy with bilateral salpingo-oophorectomy and possible lymph node dissection, often followed by adjuvant therapy. Depending on the specific histological subtype and stage, adjuvant treatment may include chemotherapy (commonly platinum-based regimens combined with taxanes), radiation therapy, or hormonal therapy. More recently, targeted therapies and immune checkpoint inhibitors have shown promise in certain subtypes, particularly those with specific molecular features such as microsatellite instability or mismatch repair deficiency. Due to the rarity of these tumors, management is best guided by multidisciplinary teams at specialized centers, and enrollment in clinical trials is encouraged when available.

Common questions about Rare uterine cancer